Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis

May 26, 2015 | Psoriasis

Use of adalimumab and infliximab for ‪#‎psoriasis‬ may lead to increased risk of serious infection http://archderm.jamanetwork.com/article.aspx?articleid=2293165

Related posts:

  1. Dermalorian™ Podcast Series: August Episode is Live!
  2. Inflammation at the Heart of Skin Disease
  3. Care Is at the Heart of World Heart Day Collaboration with DEF and SDPA
  4. FDA Considers Four New Indications for Bimzelx from UCB